Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 124, Issue 3, pp 911–914 | Cite as

Prostatic specific antigen in prostatic cancer and benign hyperplasia

  • N. E. Kushlinskii
  • N. V. Lyubimova
  • L. M. Gorilovskii
Oncology
  • 29 Downloads

Abstract

Total and free prostatic specific antigens were measured using heterogeneous two-step streptavidin enzyme immunoassay. Serum concentrations of both antigens were significantly increased in patients with prostatic cancer in comparison with those with benign hyperplasia and controls. The levels of prostatic specific antigen in patients with benign prostatic hyperplasia varied within the normal range (75%), while in 92.2% of patients with cancer these values were higher than the threshold value of 4.0 ng/ml. A statistically significant difference between the levels of total and free prostatic specific antigens reflects the difference in the expression of bound and free forms of the antigen in malignant and benign processes. Analysis of the concentrations of total antigen and the ratio of free to total prostatic specific antigen permits an accurate differentiation between cancer and benign hyperplasia of the prostate at total antigen concentrations of up to 10.0 ng/ml.

Key Words

prostatic cancer benign hyperplasia of the prostate prostatic specific antigen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    D. A. Ambruster,Clin. Chem.,39, 81–95 (1993).Google Scholar
  2. 2.
    W. J. Catalona, D. S. Smith, and T. L. Ratliff,N. Engl. J. Med.,324, 1156–1161 (1991).PubMedCrossRefGoogle Scholar
  3. 3.
    E. H. Cooper,Scand. Lab. Invest. Suppl.,206, 42–51 (1991).Google Scholar
  4. 4.
    H. Lija,Urol. Clin. North. Am.,20, 42–46 (1993).Google Scholar
  5. 5.
    A. A. Luderer, Y.-T. Chen, T. F. Soriano,et al., Urology,46, 187–194 (1995).PubMedCrossRefGoogle Scholar
  6. 6.
    R. T. McCormack, T. J. Wang, H. G. Rittenhouse,et al., ——Ibid.,,45, pp. 729–744.PubMedCrossRefGoogle Scholar
  7. 7.
    J. E. Oesterling,J. Urol.,145, 907–923 (1991).PubMedGoogle Scholar
  8. 8.
    T. A. Stamey, H. Yang, A. R. Hay,et al., N. Engl. J. Med.,317, 909–916 (1987).PubMedCrossRefGoogle Scholar
  9. 9.
    T. J. Wang, T. M. Till, R. L. Sokoloff,et al., Prostate,28, 10–16 (1996).PubMedCrossRefGoogle Scholar
  10. 10.
    M. C. Wang, L. A. Valenzuela, G. P. Murphy,et al., Invest. Urol.,17, 159–163 (1979).PubMedGoogle Scholar

Copyright information

© Plenum Plublishing Corporation 1998

Authors and Affiliations

  • N. E. Kushlinskii
    • 1
  • N. V. Lyubimova
    • 1
  • L. M. Gorilovskii
    • 1
  1. 1.N. N. Blokhin Oncology Research CenterRussian Academy of Medical SciencesMoscow

Personalised recommendations